Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Racial and Ethnic Disparities and Health Inequities in Multiple Myeloma

Premiere Date: Tuesday, October 11, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Dietetic Registration (CDR)
  7. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Saturday, October 11, 2025


Edith Peterson Mitchell, MD, MACP, FCPP, FRCPEdith Peterson Mitchell, MD, MACP, FCPP, FRCP (Moderator)
Clinical Professor of Medicine and Medical Oncology
Department of Medical Oncology
Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson
Philadelphia, PA
116th President of the National Medical Association

Joseph Mikhael, MD, MEd, FRCPC, FACPJoseph Mikhael, MD, MEd, FRCPC, FACP 
Professor, Applied Cancer Research and Drug Discovery Division
Translational Genomics Research Institute (TGen)
Phoenix, AZ
Chief Medical Officer, International Myeloma Foundation (IMF)
Studio City, CA

Statement of Need

The incidence of, and death from, multiple myeloma (MM) is 50% more in men than in women and over twice among Black people compared with White people, in spite of the fact that Black patients are more likely than White patients to have MM with a favorable risk profile. Much of these disparities in outcomes can be mitigated by providing equitable access to therapy. Among data from 9 previously published clinical trials in patients with newly diagnosed MM, adverse demographic and clinical factors were associated with inferior survival, but race was not. One of the key access points to evidence-based medicine is clinical trials, and unfortunately, non-White patients are underrepresented in clinical trials. As such, greater enrollment of non-White patients into clinical trials needs to be a priority. While there are significant disparities in MM incidence and outcomes among patients of different racial-ethnic groups, clinicians can help reduce this disparity by improving access to evidence-based medicine, including triplet therapies, stem cell transplants, CAR T-cell therapies, and clinical trials.

In this CME Outfitters podcast, expert faculty will review recent data and discuss the sweeping impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with multiple myeloma. This program will set the stage for intervention, empowering attendees to recognize and consider factors to improve multiple myeloma treatment.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Identify and describe the influence of bias, disparities, and inequities on multiple myeloma care.

Financial Support

Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.

Target Audience

Physicians, PAs, nurse practitioners, nurses, pharmacists, and dietitians, specializing in oncology, hematology, or involved in treating patients with multiple myeloma

Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning formats: Enduring material

Royal College MOC Program:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 0.5 contact hours.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Mitchell reports the following financial relationships:

Advisory Board: Corvus Pharmaceuticals, Inc.

Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.

Dr. Mikhael reports the following financial relationships:

Consultant: Amgen Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships:
  • Jeffrey Helfand, DO (peer reviewer)
  • Meghann Taft-Lockhard (planning committee)
  • David Modrak, PhD (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download